Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

被引：37

作者：

Ozeki, Michio ^{[1
]}

Nozawa, Akifumi ^{[1
]}

Kanda, Kaori ^{[1
]}

Hori, Tomohiro ^{[1
]}

Nagano, Akihito ^{[2
]}

Shimada, Akira ^{[4
]}

Miyazaki, Tatsuhiko ^{[3
]}

Fukao, Toshiyuki ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Pediat, Yanagido 1-1, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Orthoped Surg, Gifu, Japan

[3] Gifu Univ, Grad Sch Med, Dept Pathol, Gifu, Japan

[4] Okayama Univ, Dept Pediat, Grad Sch Med, Okayama, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2017年 / 39卷 / 06期

关键词：

soft tissue tumor; vascular tumor; mammalian target of rapamycin (mTOR) inhibitor; kaposiform hemangioendothelioma (KHE); phosphoinositide-3-kinase (PI3K); PLASMINOGEN-ACTIVATOR INHIBITOR-1; SARCOMA-LIKE HEMANGIOENDOTHELIOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; CANCER; SIROLIMUS; PAI-1;

D O I：

10.1097/MPH.0000000000000778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

引用

页码：E328 / E331

页数：4

共 19 条

[1] Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases
Amary, M. Fernanda
O'Donnell, Paul
Berisha, Fitim
Tirabosco, Roberto
Briggs, Tim
Pollock, Rob
Flanagan, Adrienne M.
[J]. SKELETAL RADIOLOGY, 2013, 42 (07) : 947 - 957
[2] [Anonymous], 2013, WHO CLASSIFICATION T
[3] Epithelioid Sarcoma-like Hemangioendothelioma (Pseudomyogenic Hemangioendothelioma)
Billings, Steven D.
Folpe, Andrew L.
Weiss, Sharon W.
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (07) : 1088 - 1088
[4] Treatment of Childhood Kaposiform Hemangioendothelioma With Sirolimus
Blatt, Julie
Stavas, Joseph
Moats-Staats, Billie
Woosley, John
Morrell, Dean S.
[J]. PEDIATRIC BLOOD & CANCER, 2010, 55 (07) : 1396 - 1398
[5] Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin
Declerck, Paul J.
Gils, Ann
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (04) : 356 - 364
[6] PAI-1 in tissue fibrosis
Ghosh, Asish K.
Vaughan, Douglas E.
[J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (02) : 493 - 507
[7] Pseudomyogenic Hemangioendothelioma: A Distinctive, Often Multicentric Tumor With Indolent Behavior
Hornick, Jason L.
Fletcher, Christopher D. M.
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (02) : 190 - 201
[8] Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma
Joseph, Jason
Wang, Wei-lien
Patnana, Madhavi
Ramesh, Naveen
Benjamin, Robert
Patel, Shreyaskumar
Ravi, Vinod
[J]. CLINICAL SARCOMA RESEARCH, 2015, 5
[9] SERPINE1 Intron Polymorphisms Affecting Gene Expression Are Associated With Diffuse-Type Gastric Cancer Susceptibility
Ju, Hyoungseok
Lim, Byungho
Kim, Minjin
Noh, Seung-Moo
Kim, Woo Ho
Ihm, Chunhwa
Choi, Bo Youl
Kim, Yong Sung
Kang, Changwon
[J]. CANCER, 2010, 116 (18) : 4248 - 4255
[10] Pascual J, 2006, TRANSPLANT REV, V20, P1, DOI [10.1016/j.trre.2005.10.005, DOI 10.1016/J.TRRE.2005.10.005]

← 1 2 →